Data / Form D filings / SpotitEarly, Inc.
SpotitEarly, Inc.: Form D filing
SpotitEarly, Inc., a biotechnology company in Englewood, NJ, filed a Form D with the SEC in 2025. The latest, on August 5, 2025, reports $10,000 sold of a $20 million offering to 1 investor.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 61 W. PALISADE AVE., Englewood, NJ, 07631
- Phone
- (551) 355-6554
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Year incorporated
- 2024
- Revenue range
- No Revenues
- Exemptions claimed
- Rule 506(c)
- SEC identifier (CIK)
- 2077992
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Aug 5, 2025 | New notice | $20,000,000 | $10,000 | $19,990,000 | 1 | Jul 21, 2025 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Alon Ben Lifshitz | Director | |
| Roi Leonard Ophir | Director, Promoter | |
| Shlomi Madar | Executive Officer, Director, Promoter | |
| Shai Lankry | Executive Officer, Director, Promoter | |
| Assaf Leonard Ruf | Executive Officer | |
| J. Leonard Lichtenfeld | Executive Officer | |
| Ariel Ben Dayan | Director |
Other biotechnology companies in New Jersey that filed recently
- Ensho Therapeutics, Inc. $7.3 million · Oct 15, 2026
- Xenon Ophthalmics Inc $3.3 million · Oct 6, 2026
- LISATA THERAPEUTICS, INC. $351.9 million · Oct 2, 2026
- Bullseye Biodevices, Inc. $1.3 million · Aug 10, 2026
- Hepion Pharmaceuticals, Inc. $3.1 million · Aug 5, 2026
Every Form D from the week of Aug 4, 2025 · All recent filings in New Jersey · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what SpotitEarly, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.